NICE Single Technology Appraisal Guidance No 252
Telaprevir for the treatment of genotype 1 chronic hepatitis
C
This NICE guidance was published on 25 April
2012. The web reference for the appraisal and other related
documents is: www.nice.org.uk/TA252
NHSScotland should note
that:
- Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
- NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published Statements of Advice (742/11 and
743/11) on this medication for this indication in December 2011.
Separate submissions were considered in relation to patients
previous treated and those not previously treated. The advice
stated that:
telaprevir (Incivo®) is accepted for use within
NHSScotland in combination with peginterferon alfa and ribavirin
for the treatment of genotype 1 chronic hepatitis C in adult
patients with compensated liver disease (including cirrhosis) who
have previously been treated with interferon alfa (pegylated or
non-pegylated) alone or in combination with ribavirin, including
relapsers, partial responders and null responders.
And:
telaprevir (Incivo®) is accepted for use within
NHSScotland in combination with peginterferon alfa and ribavirin,
for the treatment of genotype 1 chronic hepatitis C in adult
patients with compensated liver disease (including cirrhosis) who
are treatment-naïve.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in
the first instance
Published Date: 25 April 2012
